NCT01458288已完成2 期
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg
研究概览
简要总结
This Phase II study is to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 alone or in combination with G-CSF in Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female 18 to 75 years of age inclusive;
- •Patients with confirmed pathology diagnosis of MM, NHL or HD;
- •Potential candidate for autologous stem cell transplantation at Investigator's discretion;
- •4 weeks since last cycle of chemotherapy prior to the study drug administration;
- •Total dose of melphalan received 200 mg in the most recent chemotherapy treatment;
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- •Recovered from all acute toxic effects of prior chemotherapy at Investigator's discretion;
- •White blood cell (WBC) count 3.0 x 109/L on screening laboratory assessments;
- •Absolute neutrophil count 1.5 x 109/L on screening laboratory assessments;
- •Platelet count 100 x 109/L on screening laboratory assessments;
- •Serum creatinine 2.2 mg/dL on screening laboratory assessments;
- •Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin < 2 x upper limit of normal (ULN) on screening laboratory assessments;
- •Negative for human immunodeficiency virus (HIV);
- •Adequate cardiac and pulmonary function to undergo leukapheresis at Investigator's discretion;
- •For females, one of the following criteria must be fulfilled:
- •At least one year post-menopausal, or
- •Surgically sterile, or
- •Willing to use a double-barrier method [intrauterine device (IUD) plus condom, spermicidal gel plus condom] of contraception from study Day 1 until 28 days after the last dose of TG-0054;
- •Males must be willing to use a reliable form of contraception (use of a condom or a partner fulfilling the above criteria) from study Day 1 until 28 days after the last dose of TG-0054;
- •Able to provide the signed informed consent.
排除标准
- •Received radiation therapy to the pelvis;
- •Received > 6 cycles of lenalidomide;
- •Evidence of bone marrow involvement of lymphoma in NHL patients;
- •Failed previous stem cell collection [failed to collect 2 x 106 CD34+ cells/kg within 4 leukapheresis sessions after receiving granulocyte colony-stimulating factor (G-CSF)];
- •Patients who have undergone previous stem cell transplantation procedure;
- •Received G-CSF within 2 weeks prior to the study drug administration;
- •History of other cancer within the past 5 years excluding MM, NHL, HD, basal cell or squamous cell carcinoma of the skin;
- •History of other hematologic disorders including bleeding or thromboembolic disease being treated with anti-coagulant;
- •History of poor and uncontrollable cardiovascular or pulmonary disease such as myocardial infarction, cardiac arrhythmias, transient ischemic attack, stroke or Chronic Obstructive Pulmonary Disease (COPD) patients hospitalized more than two times a year due to underlying disease;
- •Diagnosis of sickle cell anemia or documented sickle cell trait;
- •Patients with proliferative retinopathy;
- •Uncontrollable malignancy with MM, NHL or HD, or carcinomatous meningitis, at Investigator's discretion;
- •Any infection required antibiotic treatment or unexplained fever above 38 °C within 3 days prior to dosing;
- •Pregnant or breast-feeding;
- •Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study;
- •Received any other investigational drug within 1 month before entering the study;
- •Received prior treatment with TG-0054 but withdrew early from this study.
研究组 & 干预措施
TG-0054 (3.14 mg/kg)
Experimental
TG-0054 (3.14 mg/kg)
干预措施: TG-0054 (Drug)
结局指标
主要结局
Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg
时间窗: 1 week
Patients were all with multiple myeloma (MM), Non-Hodgkin lymphoma (NHL) or Hodgkin disease (HD). Number of patients who mobilized the targeted total number of CD34+ cells within a maximum of 4 leukapheresis sessions in study arm 1 and arm 3. Patients in arm 1 followed administration of TG-0054 (3.14 mg/kg) alone and leukapheresis start from study day 1. Patients in arm 3 followed administration of TG-0054 (3.14 mg/kg) combined with granulocyte colony-stimulating factor (G-CSF) and leukapheresis start from study day 8.
次要结局
- the Average Number of Leukapheresis Sessions(1 week)
- Circulating CD34+ Cell Count in Peripheral Blood(pre-dose(-2 to 0 h),2, 4 and 6 hr after dosing.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease PatientsNon-Hodgkin LymphomaHodgkin DiseaseMultiple MyelomaNCT01018979GPCR Therapeutics, Inc.19
终止
2 期
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic MalignanciesRelated Donors Donating PBSC to a Family MemberHealthy DonorsAcute Myelogenous LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromeNCT04762875Ensoma7
Unknown
1 期
Gene Therapy for Transfusion Dependent Beta-thalassemiaBeta-ThalassemiaNCT02453477IRCCS San Raffaele10
进行中（未招募）
1 期
Gene Therapy With Modified Autologous Hematopoietic Stem Cells for the Treatment of Patients With Mucopolysaccharidosis Type I, Hurler VariantMucopolysaccharidosis IHNCT03488394Orchard Therapeutics8
已完成
1 期
Gene Therapy for Wiskott-Aldrich Syndrome (WAS)Wiskott-Aldrich SyndromeNCT01347242Genethon6